IA
KPTI icon

IndexIQ Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

IndexIQ Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$394K Buy
+3,563
New +$444K 0.01% 792

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

IndexIQ Advisors's KPTI Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2022: 3,563 shares worth $394K. The stake represents 0.01% of the portfolio and ranks #792 among its holdings.

139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • IndexIQ Advisors held 3,563 shares of Karyopharm Therapeutics worth $394K as of Q1 2022.
  • Karyopharm Therapeutics was a new IndexIQ Advisors position in Q1 2022.
  • Karyopharm Therapeutics made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #792 holding.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.